By Shaoyu Chang, MD, MPH, Senior Research Manager & Asia Business Development Liaison, LSN
Asia-based drugs, devices, diagnostics and healthcare IT companies all have a cross-border strategy. These entities have demonstrated impressive growth in recent years in terms of talent, research capacity and capital. Now on both sides of the Pacific Ocean, investors and entrepreneurs have set out to find opportunities and form new partnerships. At the Boston-Cambridge biotech hub, the tenth RESI Conference is poised to become the go-to platform for US-Asia early stage life science investments.
Life Science Nation has teamed up with a committee of highly experienced investors and organizations to implement the new Asia Track at RESI Boston. Interested attendees will have the opportunity to learn about the Asia-North America investment landscape and meet face-to-face with potential partners in biopharmaceuticals, medtech, and diagnostics.
The steering committee is composed of representatives from Wuxi Apptec, Simcere Pharmaceutical, Lyfe Capital, MP Healthcare Venture Management, Korea-Seoul Life Science Fund, Chinese-American Biomedical Association (CABA), and Sino-American Pharmaceutical Professionals Association (SAPA). The committee brings together diverse backgrounds and deep experience in early stage life science investments.
The LSN team has traveled to innovation hubs such as San Francisco, Houston, Toronto, and Boston. Everywhere we went, we were greeted by a growing number of Asia-based investors, fund managers, pharmaceutical corporations, and big corporations that are looking outside their local region for investable life science technologies. However, geographic and cultural barriers often limit their ability in deal-sourcing, evaluation, negotiation, and post-investment management.
On the other hand, many US and Canadian entrepreneurs are looking at the other side of the Pacific for capital, strategic partners, and business growth and expansion. They are faced with a different set of challenges: ignorance of risks and benefits in these new marketplaces, inability to identify a good fit from a wide array of advisors and consultants, and difficulty in establishing and maintaining long-term cooperative relationships.
The Asia Track at RESI Boston aims to address all of the above issues. Past RESI events have stressed the globalization of early stage life science investments. This time, the Asia Track will bring to you seasoned investors who understand your sector and can pinpoint emerging opportunities in China, Japan, Korea, and other Asian countries. Next Phase will announce these Asia investors panels in the coming weeks.